Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Walking away from prostate cancer: 36 men test exercise as therapy

NCT ID NCT05751434

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This phase 2 trial tests whether a personalized walking program can slow the progression of localized prostate cancer in men who are on active surveillance (monitoring instead of immediate treatment). The 36 participants will exercise up to 5 times per week for 225-300 minutes total, until their next routine biopsy (about 6-12 months later). Researchers will compare changes in tumor markers between the exercise group and a usual-care group to see if exercise makes the cancer less aggressive.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
exercise therapy
What this could lead to
If it works, this could show that a structured walking program helps keep localized prostate cancer from becoming more aggressive, potentially offering a non-drug way to manage the disease.
What could go wrong
This is a small, early-phase trial with only 36 men, so results may not apply to everyone. Exercise may not change cancer markers, and the study does not test long-term outcomes like preventing spread.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 102 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 * Men with histologically confirmed localized prostate cancer undergoing active surveillance. * Inactive, defined as not meeting the national exercise guidelines for cancer patients (\<150 minutes/week of moderate or vigorous exercise)43 as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry (general physical activity screening assessment via smart watch). * Screening clearance by an MSK Exercise Physiologist (i.e., review of ECG) * BMI \<40 kg/m\^2 * Cleared for exercise participation as per pre-screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) (Appendix B) Exclusion Criteria: * Enrollment in any other program that may alter the impact of exercise on tumor outcomes (e.g., weight loss program) * Any neoadjuvant anticancer treatment of any kind for prostate cancer in the last 5 years * Any history of systemic anticancer therapy in the last 15 years * Distant metastatic malignancy of any kind * Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Localized prostate carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Durate, California, 91010, United States

  • Hartford Healthcare Alliance (Data collection only)

    NOT_YET_RECRUITING

    Hartford, Connecticut, 06102, United States

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    NOT_YET_RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited protocol activities)

    NOT_YET_RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    NOT_YET_RECRUITING

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Monmouth (Limited protocol activities)

    NOT_YET_RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited protocol activites)

    NOT_YET_RECRUITING

    Rockville Centre, New York, 11553, United States

  • Memorial Sloan Kettering Suffolk - Commack (Limited protocol activities)

    NOT_YET_RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Westchester (Limited protocol activities)

    NOT_YET_RECRUITING

    Harrison, New York, 10604, United States

  • University of California, Los Angeles (Data and Specimen Analysis Only)

    NOT_YET_RECRUITING

    Los Angeles, California, 90095-1781, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.